The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-23), Cogent Biosciences's share price is $6.96. Cogent Biosciences's Book Value per Share for the quarter that ended in Dec. 2023 was $2.30. Hence, Cogent Biosciences's PB Ratio of today is 3.03.
The historical rank and industry rank for Cogent Biosciences's PB Ratio or its related term are showing as below:
COGT'
s PB Ratio Range Over the Past 10 Years
Min: 0.31 Med: 2.56 Max: 6.35
Current: 3.03
During the past 9 years, Cogent Biosciences's highest PB Ratio was 6.35. The lowest was 0.31. And the median was 2.56.
COGT's PB Ratio is ranked worse than 60.08% of 1310
companies
in the Biotechnology industry
Industry Median: 2.36
vs COGT: 3.03
During the past 12 months, Cogent Biosciences's average Book Value Per Share Growth Rate was -15.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -15.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -19.90% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Cogent Biosciences was -13.10% per year. The lowest was -28.40% per year. And the median was -15.70% per year.
Back to Basics: PB Ratio
Cogent Biosciences PB Ratio Historical Data
The historical data trend for Cogent Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cogent Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences PB Ratio Distribution
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's PB Ratio falls into.
Cogent Biosciences PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Cogent Biosciences's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cogent Biosciences (NAS:COGT) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cogent Biosciences PB Ratio Related Terms
Thank you for viewing the detailed overview of Cogent Biosciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Cogent Biosciences (Cogent Biosciences) Business Description
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COGT has been successfully added to your 